Stocks · Health care · Biological Products, (No Diagnostic Substances)

RECURSION PHARMACEUTICALS, INC.

RXRX Clue Score60
United States Fiscal year ends December CIK 0001601830 Results filed 2 Nov 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Christopher Gibson
30 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Christopher Gibson
29 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Christopher Gibson
28 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Christopher Gibson
27 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Christopher Gibson
26 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Christopher Gibson
23 Aug 2024
Chief Executive Officer
Exercised, kept
5,000
$2.48
$12.40K
Showing 250 of 464 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 479
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 22
Sales on a Rule 10b5-1 plan 57
Sales straight out of an exercise 308
Sales at will 56
Transactions with no price 0
Shares from compensation/vesting 217,995,789
Sales filed before the plan box existed 31
History held since 19 Apr 2021